Company / Current Liabilities
Voyager Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$26.5M
FY2025
5-year range
$26.5M / $72.6M
FY2021-FY2025
Trend
-46.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has declined for 3 consecutive years, from $73M in FY2022 to $27M in FY2025.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of -0.2%.
Improved from $65M to $27M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -28.5%
- 5-Year CAGR
- -0.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- Voyager Therapeutics, Inc.'s current liabilities has declined for 3 consecutive years.
- 5-year CAGR of -0.2%, indicating a declining trend.
- In FY2025, current liabilities decreased 46.7% year-over-year.
- Peak current liabilities was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.5M | -46.7% |
| FY2024 | $49.8M | -22.8% |
| FY2023 | $64.5M | -11.1% |
| FY2022 | $72.6M | +42.4% |
| FY2021 | $51.0M | +90.5% |
| FY2020 | $26.8M | -64.8% |
| FY2019 | $76.0M | +140.0% |
| FY2018 | $31.7M | +99.2% |
| FY2017 | $15.9M | +15.2% |
| FY2016 | $13.8M | -42.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026